All Stories

  1. TASK-3, two-pore potassium channels, contribute to circadian rhythms in the electrical properties of the suprachiasmatic nucleus and play a role in driving stable behavioural photic entrainment
  2. The Contribution of Genetic Sequencing Information to the Identification and Functional Characterization of Two-Pore Domain Potassium (K2P) Channels as Viable Therapeutic Targets
  3. Screening for atrial fibrillation in care homes using pulse palpation and the AliveCor Kardia Mobile® device: a comparative cross-sectional pilot study
  4. The Concise Guide to PHARMACOLOGY 2023/24: Catalytic receptors
  5. The Concise Guide to PHARMACOLOGY 2023/24: Enzymes
  6. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
  7. The Concise Guide to PHARMACOLOGY 2023/24: Introduction and Other Protein Targets
  8. The Concise Guide to PHARMACOLOGY 2023/24: Ion channels
  9. The Concise Guide to PHARMACOLOGY 2023/24: Nuclear hormone receptors
  10. The Concise Guide to PHARMACOLOGY 2023/24: Transporters
  11. A KCNB1 gain of function variant causes developmental delay and speech apraxia but not seizures
  12. HIV and Schistosoma Co-Exposure Leads to Exacerbated Pulmonary Endothelial Remodeling and Dysfunction Associated with Altered Cytokine Landscape
  13. Gain and loss of TASK3 channel function and its regulation by novel variation cause KCNK9 imprinting syndrome
  14. Aprepitant is a novel, selective activator of the K2P channel TRAAK
  15. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors
  16. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes
  17. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
  18. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and Other Protein Targets
  19. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels
  20. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Nuclear hormone receptors
  21. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters
  22. Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092
  23. The Prostacyclin Analogue, Treprostinil, Used in the Treatment of Pulmonary Arterial Hypertension, is a Potent Antagonist of TREK-1 and TREK-2 Potassium Channels
  24. Pharmacological Approaches to Studying Potassium Channels
  25. A “Target Class” Screen to Identify Activators of Two-Pore Domain Potassium (K2P) Channels
  26. Heterologous Expression of Ion Channels in Mammalian Cell Lines
  27. TRESK is a key regulator of nocturnal suprachiasmatic nucleus dynamics and light adaptive responses
  28. TASK-3 Two-Pore Potassium Channels drive neuronal excitability of the circadian clock and entrainment to challenging light environments
  29. Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season: A cross-sectional feasibility study
  30. Two-Pore Domain Potassium Channels as Drug Targets: Anesthesia and Beyond
  31. Pharmacists detecting atrial fibrillation in general practice: a qualitative focus group study
  32. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
  33. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes
  34. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors
  35. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets
  36. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels
  37. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors
  38. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters
  39. Pranlukast is a novel small molecule activator of the two-pore domain potassium channel TREK2
  40. Pharmacologically reversible, loss of function mutations in the TM2 and TM4 inner pore helices of TREK-1 K2P channels
  41. Effects of the ventilatory stimulant, doxapram on human TASK‐3 (KCNK9, K2P9.1) channels and TASK‐1 (KCNK3, K2P3.1) channels
  42. Infection in pulmonary vascular diseases: Would another consortium really be the way to go?
  43. Characterisation and regulation of wild type and mutant TASK-1 two pore domain potassium channels indicated in pulmonary arterial hypertension
  44. HIV transgene expression impairs K+ channel function in the pulmonary vasculature
  45. Activation of TREK currents by riluzole in three subgroups of cultured mouse nodose ganglion neurons
  46. Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol
  47. GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K2P ) channel opener, reduces rat dorsal root ganglion neuron excitability
  48. TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications
  49. Terbinafine is a novel and selective activator of the two-pore domain potassium channel TASK3
  50. Enhanced inflammatory cell profiles in schistosomiasis-induced pulmonary vascular remodeling
  51. Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels
  52. Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain
  53. Influence of the N Terminus on the Biophysical Properties and Pharmacology of TREK1 Potassium Channels
  54. Enhancement of Current through Trek1 Two Pore Domain Channels by Flufenamic Acid
  55. Recovery of Current through Mutated TASK3 Potassium Channels Underlying Birk Barel Syndrome
  56. Enhancement of TWIK-related Acid-sensitive Potassium Channel 3 (TASK3) Two-pore Domain Potassium Channel Activity by Tumor Necrosis Factor  
  57. GuideToPharmacology.org - an update
  58. Guide to Receptors and Channels (GRAC), 5th edition
  59. Trafficking of Neuronal Two Pore Domain Potassium Channels
  60. SYMPOSIUM REVIEW: Gating of two pore domain potassium channels
  61. Ion channels as novel therapeutic targets in the treatment of pain
  62. Dominant Negative Effects of a Non-conducting TREK1 Splice Variant Expressed in Brain
  63. Guide to Receptors and Channels (GRAC), 4th edition
  64. The M1P1 Loop of TASK3 K2P Channels Apposes the Selectivity Filter and Influences Channel Function
  65. Guide to Receptors and Channels (GRAC), 3rd edition
  66. Identification of a region in the TASK3 two pore domain potassium channel that is critical for its blockade by methanandamide
  67. TASK-3 Two-Pore Domain Potassium Channels Enable Sustained High-Frequency Firing in Cerebellar Granule Neurons
  68. Gαq-Mediated Regulation of TASK3 Two-Pore Domain Potassium Channels: The Role of Protein Kinase C
  69. Guide to Receptors and Channels, 2nd edition (2007 Revision)
  70. Neuronal two-pore-domain potassium channels and their regulation by G protein-coupled receptors
  71. Zinc and copper: Pharmacological probes and endogenous modulators of neuronal excitability
  72. Guide to Receptors and Channels, 2nd edition
  73. The in Vivo Contributions of TASK-1-Containing Channels to the Actions of Inhalation Anesthetics, the α2 Adrenergic Sedative Dexmedetomidine, and Cannabinoid Agonists
  74. Modifying the Subunit Composition of TASK Channels Alters the Modulation of a Leak Conductance in Cerebellar Granule Neurons
  75. Guide to Receptors and Channels, 1st Edition (2005 revision)
  76. Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine
  77. Selective block of the human 2-P domain potassium channel, TASK-3, and the native leak potassium current, IKSO, by zinc
  78. Two-Pore-Domain K+ Channels Are a Novel Target for the Anesthetic Gases Xenon, Nitrous Oxide, and Cyclopropane
  79. Neuronal ion channels and their sensitivity to extremely low frequency weak electric field effects
  80. What are the roles of the many different types of potassium channel expressed in cerebellar granule cells?
  81. What are the roles of the many different types of potassium channel expressed in cerebellar granule cells?
  82. Background potassium channels move into focus
  83. Pharmacological characterization of a non-inactivating outward current observed in mouse cerebellar Purkinje neurones
  84. Inhibition of the potassium current IKSO, in cerebellar granule cells, by the inhibitors of MEK1 activation, PD 98059 and U 0126
  85. MAMMALIAN TWO-PORE DOMAIN POTASSIUM CHANNELS
  86. TiPS nomenclature supplement 2001
  87. The role of Ca2+stores in the muscarinic inhibition of the K+currentIK(SO)in neonatal rat cerebellar granule cells
  88. Purinergic and muscarinic receptor activation activates a common calcium entry pathway in rat neocortical neurons and glial cells
  89. A functional role for the two-pore domain potassium channel TASK-1 in cerebellar granule neurons
  90. A functional role for the two-pore domain potassium channel TASK-1 in cerebellar granule neurons
  91. Inhibition of delayed rectifier K+conductance in cultured rat cerebellar granule neurons by activation of calcium-permeable AMPA receptors
  92. Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine
  93. Inhibition by inorganic ions of a sustained calcium signal evoked by activation of mGlu5 receptors in rat cortical neurons and glia
  94. Activation of group I metabotropic glutamate receptors elicits pH changes in cultured rat cortical glia and neurons
  95. Characterization of the hyperpolarization-activated chloride current in dissociated rat sympathetic neurons
  96. Voltage-activated potassium channels in mammalian neurons and their block by novel pharmacological agents
  97. Ion Channels: Molecules in Action. Edited by D. J.Aidleyand P. R.Stanfield. Pp. 340. Cambridge University Press, 1996. £17.95 paperback, ISBN 0521 49882 1. £50.00 hardback, ISBN 0 521 49531 8
  98. Is eag the answer to the M-current?
  99. Effects on K+ currents in rat cerebellar granule neurones of a membrane-permeable analogue of the calcium chelator BAPTA
  100. A non-inactivating K+ current sensitive to muscarinic receptor activation in rat cultured cerebellar granule neurons.
  101. Potent block of potassium currents in rat isolated sympathetic neurones by the uncharged form of amitriptyline and related tricyclic compounds
  102. Methods in neurosciences volume 19: Ion channels of excitable cells
  103. Multiple G-protein-coupled pathways inhibit N-type Ca channels of neurons
  104. Modulation of the gating of the transient outward potassium current of rat isolated cerebellar granule neurons by lanthanum
  105. Block of potassium currents in rat isolated sympathetic neurones by tricyclic antidepressants and structurally related compounds
  106. Characterization of muscarinic receptor subtypes inhibiting Ca2+ current and M current in rat sympathetic neurons.
  107. Inhibition of N- and L-type calcium channels by muscarinic receptor activation in rat sympathetic neurons
  108. 5-HT3 receptor channels in dissociated rat superior cervical ganglion neurons.
  109. Conductance and kinetic properties of single nicotinic acetylcholine receptor channels in rat sympathetic neurones.
  110. Intracellular Ca2+ buffers disrupt muscarinic suppression of Ca2+ current and M current in rat sympathetic neurons.
  111. Activation of glutamate receptors and glutamate uptake in identified macroglial cells in rat cerebellar cultures.
  112. Rectification of currents activated by nicotinic acetylcholine receptors in rat sympathetic ganglion neurones.
  113. Chapter 5 Function of nicotinic synapses
  114. Acetylcholine receptor channels and their block by clonidine in cultured bovine chromaffin cells.
  115. Nicotinic acetylcholine receptors of nerve and muscle: Functional aspects
  116. Single-Channel and Whole-Cell Currents Evoked by Acetylcholine in Dissociated Sympathetic Neurons of the Rat
  117. Interactions between the effects of yohimbine, clonidine and [Ca]o on the electrical response of the mouse vas deferens
  118. Ion channels activated by acetylcholine and γ-aminobutyric acid in freshly dissociated sympathetic neurones of the rat
  119. Facilitation at single release sites of a sympathetic neuroeffector junction in the mouse.
  120. α-ADRENORECEPTORS AND FACILITATION AT A SYMPATHETIC NEUROEFFECTOR JUNCTION
  121. Neuronal Potassium Channels